Movement Alert｜ImmunityBio, Inc. Intraday Decline 18.6% in Regular Trading, Q3 Loss and Revenue Miss Overshadow Trial Update

Market Focus11-09

On November 9, ImmunityBio, Inc. fell 18.6% in Regular Trading, trading at $6.9601 per share, with turnover of $36.3608 million.

The clearest catalyst was the company’s third-quarter report: adjusted EPS was a loss of $0.09, missing the consensus loss of $0.08, while revenue was $48.841 million, below the $59.250 million estimate. Separately, reported net loss widened to $0.18 per diluted share from a loss of $0.07 a year earlier, even as revenue rose from $32.1 million.

ImmunityBio, Inc. also said Anktiva in combination with BCG met the primary endpoint in a registrational non-muscle invasive bladder cancer trial and remains on track for a supplemental biologics filing by the end of 2026. However, the sharp move appears more directly aligned with the earnings miss and wider loss than with the clinical update or the earlier Europe commercial-treatment milestone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment